Novartis: Dermatitis, Atopic trials
The registry lists 31 Dermatitis, Atopic studies with Novartis as lead sponsor. 2 are open to participants now and 5 have results posted.
Phase 1 5Phase 2 7Phase 3 5Phase 4 13No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic DermatitisRecruitingNCT07604324Phase 1
- Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic DermatitisRecruitingNCT06947993Phase 2
- A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.CompletedNCT04836858Phase 2Results posted
- A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis PatientsTerminatedNCT03948334Phase 2Results posted
- A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic DermatitisTerminatedNCT03517566Phase 2Results posted
- Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.CompletedNCT01785602Phase 2Results posted
- Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease ModificationTerminatedNCT00124709Phase 4Results posted
- Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic DermatitisActive, not recruitingNCT07220577Phase 2
- A First-in-Human Study of CEE321 in Adult SubjectsCompletedNCT04612062Phase 1
- Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064CompletedNCT03918980Phase 1
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male SubjectsCompletedNCT01596712Phase 1
- A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis PatientsCompletedNCT01552629Phase 2
- A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton SyndromeCompletedNCT01428297Phase 1
- Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under OcclusionCompletedNCT00925730Phase 4
- Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-oldCompletedNCT00510003Phase 4
- Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical SettingCompletedNCT00509990Phase 4
- A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic DermatitisCompletedNCT00484003Phase 4
- Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic DermatitisCompletedNCT00367393Phase 4
- Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic DermatitisCompletedNCT00351052Phase 3
- Verification Study of Ciclosporin for Atopic DermatitisCompletedNCT00232076Phase 3
- Long-term Study of Ciclosporin for Atopic DermatitisCompletedNCT00232063Phase 3
- Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic DermatitisCompletedNCT00232011Phase 3
- Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic DermatitisCompletedNCT00231998Phase 3
- Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic DermatitisCompletedNCT00150059Phase 4
- Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric SubjectsCompletedNCT00139581Phase 4
- Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic DermatitisCompletedNCT00130364Phase 4
- Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic DermatitisCompletedNCT00121381Phase 4
- Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) PatientsCompletedNCT00121316Phase 4
- Quality of Life Study in Adults With Facial EczemaCompletedNCT00120302Phase 4
- Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic DermatitisCompletedNCT00117377Phase 4
- Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Atopic DermatitisCompletedNCT00098150